▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Amy Ho

amyfaithho

Medical provider. Emergency medicine. Interest in biotech. Background in online retail.

Recent Articles by Amy Ho

Jan 24, 2014 by Amy Ho

UK Eyes Success of US FDA Breakthrough Designation Program

Expedited review of drugs in UK would be a win for patients, even bigger win for investors

Jan 22, 2014 by Amy Ho

Bristol-Myers Squibb Hepatitis C Therapy Opens Up Combination Options

Bristol-Myers Squibb breaks from seeking a combination with Gilead on hepatitis C treatment.

Jan 17, 2014 by Amy Ho

Merck & Co., Inc. Reinvigorates R&D With Emphasis On Cancer Immunotherapy

Merck's aggressive plan will likely spur competitors Roche and Bristol-Myers Squibb

Jan 15, 2014 by Amy Ho

Alnylam Partnership Signal Revitalizing of RNAi Therapeutics

Merck backs away while Sanofi ups its share.

Dec 13, 2013 by Amy Ho

FDA Takes Issue with Takeda's Prospective 2014 Approval of Vedolizumab

Concerns over infection risks spurred action from an FDA advisory panel regarding the approval of the inflammatory bowel disease treatment vedolizumab.

Dec 11, 2013 by Amy Ho

Novartis Strengthens in Oncology With Multiple Myeloma

Novartis' strong R&D proves itself in the face of rivals' acquisitions and restructuring

Dec 10, 2013 by Amy Ho

Gilead's Sofosbuvir Gains FDA Approval, Attracts Patent Battle

Race for new hepatitis C therapy riddled with patent complications.

Dec 10, 2013 by Amy Ho

Eli Lilly Struggles for Pipeline Success

Edivoxetine failure dampens Lilly's R&D efforts

Dec 10, 2013 by Amy Ho

Iclusig Troubles Continue for Ariad in Europe

Ariad's leukemia agent struggles with European regulators after the FDA pulled its product.

Dec 4, 2013 by Amy Ho

Mylan Nabs India, Roche Takes Europe in Breast Cancer Therapies

Mylan and Biocon gain approval for Herceptin biosimilar in India while Roche and ImmunoGen gain approval for Herceptin-DM1 combination Kadcyla in Europe.

Dec 4, 2013 by Amy Ho

AstraZeneca Eyes Forest Labs as Shares Rise

Forest Laboratories makes significant company improvements as AstraZeneca considers possible buyout.

Dec 2, 2013 by Amy Ho

Repros Poised to Take On Growing Testosterone Market

Repros wins meeting with FDA for oral testosterone frontrunner Androxal after FDA concerns last month tanked shares

Nov 11, 2013 by Amy Ho

Potential for Anti-NGF Agents Builds With Partnership Between Pfizer and Eli Lilly

Pfizer and Eli Lilly collaboration may mark new beginnings for high-risk class of drugs

Nov 6, 2013 by Amy Ho

Troubled Merck Puts Hopes in New HPV Vaccine

Merck announces positive phase 3 results for its next-generation HPV vaccine V503.

Nov 5, 2013 by Amy Ho

Bristol-Myers Squibb First to Japan in New Hepatitis C Therapy Race

Bristol-Myers Squibb files for approval in Japan of first ever all-oral and interferon- and ribavirin-free hepatitis C treatment.

Nov 4, 2013 by Amy Ho

Roche's Gazyva Approval Marks Success in Oncology and New FDA Designation

The FDA's first therapy given the Breakthrough Therapy designation gains approval, paving the way for competitors.

Nov 1, 2013 by Amy Ho

Gilead Sciences and Johnson & Johnson Push Vertex Out of Hepatitis C Race

Vertex announces job cuts and focus towards cystic fibrosis amid Food and Drug Administration moves on competiting hepatitis C therapies.

Nov 1, 2013 by Amy Ho

FDA Approves New Alzheimer's Diagnostic Agent but Medicare and Markets Yet to Follow

A look at GE (NYSE: GE) Healthcare's newly-approved Alzheimer's imaging agent, and other players in this space like Eli Lilly (NYSE: LLY), Merck (NYSE: MRK), and Navidea Biopharmaceuticals (NYSEMRK: NAVB).

Oct 31, 2013 by Amy Ho

Nutrisystem Earnings Bulk Up the Weight-Loss Space

Weight-loss companies Nutrisystem, Weight Watchers and Medifast face unique challenges as consumers fatten up for diet season.

Oct 30, 2013 by Amy Ho

Pfizer Earnings Report Rounds Out Dow Pharmaceuticals Outlook

Pfizer falls in middle of struggling Merck and stable Johnson & Johnson in recent big pharma earnings reports.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services